Cargando…

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients

A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin®) + 5-fluorouracil (5-FU) ± folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorect...

Descripción completa

Detalles Bibliográficos
Autores principales: Bensmaïne, M A, Marty, M, Gramont, A de, Brienza, S, Lévi, F, Ducreux, M, François, E, Gamelin, E, Bleiberg, H, Cvitkovic, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364084/
https://www.ncbi.nlm.nih.gov/pubmed/11506488
http://dx.doi.org/10.1054/bjoc.2001.1953
_version_ 1782153865730195456
author Bensmaïne, M A
Marty, M
Gramont, A de
Brienza, S
Lévi, F
Ducreux, M
François, E
Gamelin, E
Bleiberg, H
Cvitkovic, E
author_facet Bensmaïne, M A
Marty, M
Gramont, A de
Brienza, S
Lévi, F
Ducreux, M
François, E
Gamelin, E
Bleiberg, H
Cvitkovic, E
author_sort Bensmaïne, M A
collection PubMed
description A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin®) + 5-fluorouracil (5-FU) ± folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorectal cancer (ACRC). 481 5-FU-resistant ACRC patients, most with performance status ≤ 2, ≥ 3 involved sites, and ≥ 2 prior lines of chemotherapy, received oxaliplatin + 5-FU ± FA. Prognostic factors associated with overall response rate (ORR), time to progression (TTP) and overall survival (OS) were identified using univariate and multivariate logistic and/or Cox proportional hazards analyses. The ORR was 16% (95% CI: 13–20), the median TTP was 4.2 months (95% CI: 3.4–4.6), and the median OS was 9.6 months (95% CI: 8.6–10.6). The multivariate analysis indicated poor (≥ 2 WHO) performance status (PS), a large number of prior chemotherapy regimens (≥ 3), a low baseline haemoglobin level (< 10 g/dl), and a triweekly (vs biweekly) treatment administration schedule as significantly associated (P< 0.05) with a lower ORR. Sex (male), number of organs involved (≥3) and alkaline phosphatase (AP) level (≥ 2 × the upper limit of normal) were associated (P< 0.05) with shorter TTP. Poor PS, a large number of organs involved, and elevated AP were independently and significantly correlated with shorter OS. Our analysis identified a relationship between efficacy results of oxaliplatin + 5-FU ± FA treatment in 5-FU-resistant ACRC patients and baseline prognostic factors related to PS, extent of disease and number of prior regimens. © 2001 Cancer Research Campaign http://www.bjcancer.com
format Text
id pubmed-2364084
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23640842009-09-10 Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients Bensmaïne, M A Marty, M Gramont, A de Brienza, S Lévi, F Ducreux, M François, E Gamelin, E Bleiberg, H Cvitkovic, E Br J Cancer Regular Article A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin®) + 5-fluorouracil (5-FU) ± folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorectal cancer (ACRC). 481 5-FU-resistant ACRC patients, most with performance status ≤ 2, ≥ 3 involved sites, and ≥ 2 prior lines of chemotherapy, received oxaliplatin + 5-FU ± FA. Prognostic factors associated with overall response rate (ORR), time to progression (TTP) and overall survival (OS) were identified using univariate and multivariate logistic and/or Cox proportional hazards analyses. The ORR was 16% (95% CI: 13–20), the median TTP was 4.2 months (95% CI: 3.4–4.6), and the median OS was 9.6 months (95% CI: 8.6–10.6). The multivariate analysis indicated poor (≥ 2 WHO) performance status (PS), a large number of prior chemotherapy regimens (≥ 3), a low baseline haemoglobin level (< 10 g/dl), and a triweekly (vs biweekly) treatment administration schedule as significantly associated (P< 0.05) with a lower ORR. Sex (male), number of organs involved (≥3) and alkaline phosphatase (AP) level (≥ 2 × the upper limit of normal) were associated (P< 0.05) with shorter TTP. Poor PS, a large number of organs involved, and elevated AP were independently and significantly correlated with shorter OS. Our analysis identified a relationship between efficacy results of oxaliplatin + 5-FU ± FA treatment in 5-FU-resistant ACRC patients and baseline prognostic factors related to PS, extent of disease and number of prior regimens. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-08 /pmc/articles/PMC2364084/ /pubmed/11506488 http://dx.doi.org/10.1054/bjoc.2001.1953 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Bensmaïne, M A
Marty, M
Gramont, A de
Brienza, S
Lévi, F
Ducreux, M
François, E
Gamelin, E
Bleiberg, H
Cvitkovic, E
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
title Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
title_full Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
title_fullStr Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
title_full_unstemmed Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
title_short Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
title_sort factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-fu) ± folinic acid in a compassionate-use cohort of 481 5-fu-resistant advanced colorectal cancer patients
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364084/
https://www.ncbi.nlm.nih.gov/pubmed/11506488
http://dx.doi.org/10.1054/bjoc.2001.1953
work_keys_str_mv AT bensmainema factorspredictingefficacyofoxaliplatinincombinationwith5fluorouracil5fufolinicacidinacompassionateusecohortof4815furesistantadvancedcolorectalcancerpatients
AT martym factorspredictingefficacyofoxaliplatinincombinationwith5fluorouracil5fufolinicacidinacompassionateusecohortof4815furesistantadvancedcolorectalcancerpatients
AT gramontade factorspredictingefficacyofoxaliplatinincombinationwith5fluorouracil5fufolinicacidinacompassionateusecohortof4815furesistantadvancedcolorectalcancerpatients
AT brienzas factorspredictingefficacyofoxaliplatinincombinationwith5fluorouracil5fufolinicacidinacompassionateusecohortof4815furesistantadvancedcolorectalcancerpatients
AT levif factorspredictingefficacyofoxaliplatinincombinationwith5fluorouracil5fufolinicacidinacompassionateusecohortof4815furesistantadvancedcolorectalcancerpatients
AT ducreuxm factorspredictingefficacyofoxaliplatinincombinationwith5fluorouracil5fufolinicacidinacompassionateusecohortof4815furesistantadvancedcolorectalcancerpatients
AT francoise factorspredictingefficacyofoxaliplatinincombinationwith5fluorouracil5fufolinicacidinacompassionateusecohortof4815furesistantadvancedcolorectalcancerpatients
AT gameline factorspredictingefficacyofoxaliplatinincombinationwith5fluorouracil5fufolinicacidinacompassionateusecohortof4815furesistantadvancedcolorectalcancerpatients
AT bleibergh factorspredictingefficacyofoxaliplatinincombinationwith5fluorouracil5fufolinicacidinacompassionateusecohortof4815furesistantadvancedcolorectalcancerpatients
AT cvitkovice factorspredictingefficacyofoxaliplatinincombinationwith5fluorouracil5fufolinicacidinacompassionateusecohortof4815furesistantadvancedcolorectalcancerpatients